Recent CPP-based applications in medicine

References

• Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55(6):1189–1193.
   PubMed Web of Science ®Google Scholar
• Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 1988;55(6):1179–1188.
   PubMed Web of Science ®Google Scholar
• Langel Ü. CPP, cell-penetrating peptides. Vol. XII. 1 ed. Singapore: Springer; 2019. p. 470.
   Google Scholar
• Kurrikoff K, Gestin M, Langel Ü. Recent in vivo advances in cell-penetrating peptide-assisted drug delivery. Expert Opin Drug Deliv. 2016;13(3):373–387.
   PubMed Web of Science ®Google Scholar
• Langel Ü, editor. Cell-penetrating peptides. Methods and protocols. 2nd Edition. New York: Humana Press; 2015. p. 472.
   Google Scholar
• Uusna J, Langel K, Langel Ü. Toxicity, immunogenicity, uptake, and kinetics methods for CPPs. Methods Mol Biol. 2015;1324:133–148.
   PubMedGoogle Scholar
• Lehto T, Kurrikoff K, Langel Ü. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv. 2012;9(7):823–836.
   PubMed Web of Science ®Google Scholar
• Kurrikoff K, Aphkhazava D, Langel Ü. The future of peptides in cancer treatment. Curr Opin Pharmacol. 2019;47:27–32.
   PubMed Web of Science ®Google Scholar
• Jones S, Osman S, Howl J. A high-throughput synthetic platform enables the discovery of proteomimetic cell penetrating peptides and bioportides. Int J Pept Res Ther. 2019;25(1):1–8.
   Web of Science ®Google Scholar
• Bennett G, Lutz R, Park P, et al. Abstract 1167: development of BT1718, a novel Bicycle Drug Conjugate for the treatment of lung cancer. Cancer Res. 2017;77(13 Supplement):1167.
   Google Scholar
• Arrouss I, Nemati F, Roncal F, et al. Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy. PLoS One. 2013;8(4):e60816.
   PubMed Web of Science ®Google Scholar
• Zhang X, Brossas JY, Parizot C, et al. Identification and characterization of novel enhanced cell penetrating peptides for anti-cancer cargo delivery. Oncotarget. 2018;9(5):5944–5957.
   PubMedGoogle Scholar
• Guergnon J, Dessauge F, Dominguez V, et al. Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol. 2006;69(4):1115–1124.
   PubMed Web of Science ®Google Scholar
• Tian L, Zhang X, Haesen D, et al., Identification of PP2A/set binding sites and design of interacting peptides with potential clinical applications. Int J Pept Res Ther. 2018;24(4):479–488.
   Web of Science ®Google Scholar
• Jagot-Lacoussiere L, Kotula E, Villoutreix BO, et al. A cell-penetrating peptide targeting AAC-11 specifically induces cancer cells death. Cancer Res. 2016;76(18):5479–5490.
   PubMed Web of Science ®Google Scholar
• Muller R, Misund K, Holien T, et al. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013;8(7):e70430.
   PubMed Web of Science ®Google Scholar
• Sogaard CK, Blindheim A, Røst LM, et al. “Two hits - one stone”; increased efficacy of cisplatin-based therapies by targeting PCNA’s role in both DNA repair and cellular signaling. Oncotarget. 2018;9(65):32448–32465.
   PubMedGoogle Scholar
• Soussi T, Wiman KG. TP53: an oncogene in disguise. Cell Death Differ. 2015;22(8):1239–1249.
   PubMed Web of Science ®Google Scholar
• Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132–147.e16.
   PubMed Web of Science ®Google Scholar
• Yamada T, Mehta RR, Lekmine F, et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol Cancer Ther. 2009;8(10):2947–2958.
   PubMed Web of Science ®Google Scholar
• Yamada T, Das Gupta TK, Beattie CW. p28-Mediated activation of p53 in G2-M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy. Cancer Res. 2016;76(8):2354–2365.
   PubMed Web of Science ®Google Scholar
• Warso MA, Richards JM, Mehta D, et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer. 2013;108(5):1061–1070.
   PubMed Web of Science ®Google Scholar
• Lulla RR, Goldman S, Yamada T, et al. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2016;18(9):1319–1325.
   PubMed Web of Science ®Google Scholar
• Carvajal LA, Neriah DB, Senecal A, et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018;10(436).
   Web of Science ®Google Scholar
• Meric-Bernstam F, Saleh MN, Infante JR, et al. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J Clin Oncol. 2017;35(15_suppl):2505.
   Google Scholar
• Lucchesi CA, Zhang J, Ma B, et al. Disruption of the Rbm38-eIF4E complex with a synthetic peptide Pep8 increases p53 expression. Cancer Res. 2019;79(4):807–818.
   PubMed Web of Science ®Google Scholar
• Dardevet L, Rani D, Abd El Aziz T, et al. Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion, in Toxins (Basel). 2015:1079–1101.
   Google Scholar
• Diaz-Perlas C, Varese M, Guardiola S, et al. From venoms to BBB-shuttles. MiniCTX3: a molecular vector derived from scorpion venom. Chem Commun (Camb). 2018;54(90):12738–12741.
   PubMed Web of Science ®Google Scholar
• Gait MJ, Arzumanov AA, McClorey G, et al. Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment. Nucleic Acid Ther. 2019;29(1):1–12.
   PubMed Web of Science ®Google Scholar
• Shabanpoor F, Hammond SM, Abendroth F, et al. Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy. Nucleic Acid Ther. 2017;27(3):130–143.
   PubMed Web of Science ®Google Scholar
• Kauffman WB, Guha S, Wimley WC. Synthetic molecular evolution of hybrid cell penetrating peptides. Nat Commun. 2018;9(1):2568.
   PubMedGoogle Scholar
• Bender E. Gene therapy: industrial strength. Nature. 2016;537(7619):S57–S9.
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang J, Meng F, et al. cRGD/TAT dual-ligand reversibly cross-linked micelles loaded with docetaxel penetrate deeply into tumor tissue and show high antitumor efficacy in Vivo. ACS Appl Mater Interfaces. 2017;9(41):35651–35663.
   PubMed Web of Science ®Google Scholar
• Roder R, Helma J, Preiß T, et al. Intracellular delivery of nanobodies for imaging of target proteins in live cells. Pharm Res. 2017;34(1):161–174.
   PubMed Web of Science ®Google Scholar
• Veiman K-L, Künnapuu K, Lehto T, et al. PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. J Control Release. 2015;209:238–247.
   PubMed Web of Science ®Google Scholar
• Künnapuu K, Veiman K-L, Porosk L, et al., Tumor gene therapy by systemic delivery of plasmid DNA with cell penetrating peptides. FASEB BioAdv. 2018;1(2):105–114.
   PubMedGoogle Scholar
• Salzano G, Costa DF, Sarisozen C, et al. Mixed nanosized polymeric micelles as promoter of doxorubicin and miRNA-34a co-delivery triggered by dual stimuli in tumor tissue. Small. 2016;12(35):4837–4848.
   PubMed Web of Science ®Google Scholar
• Sun CY, Shen S, Xu C-F, et al. Tumor acidity-sensitive polymeric vector for active targeted siRNA delivery. J Am Chem Soc. 2015;137(48):15217–15224.
   PubMed Web of Science ®Google Scholar
• Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004;101(51):17867–17872.
   PubMed Web of Science ®Google Scholar
• Tang B, Zaro JL, Shen Y, et al. Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting. J Control Release. 2018;279:147–156.
   PubMed Web of Science ®Google Scholar
• Shi NQ, Li Y, Zhang Y, et al. Intelligent “Peptide-gathering mechanical arm” Tames Wild “Trojan-Horse” peptides for the controlled delivery of cancer nanotherapeutics. ACS Appl Mater Interfaces. 2017;9(48):41767–41781.
   PubMed Web of Science ®Google Scholar
• Hager S, Wagner E. Bioresponsive polyplexes - chemically programmed for nucleic acid delivery. Expert Opin Drug Deliv. 2018;15(11):1067–1083.
   PubMed Web of Science ®Google Scholar
• Luo J, Xie Z, Lam JWY, et al. Aggregation-induced emission of 1-methyl-1,2,3,4,5-pentaphenylsilole. Chem Commun (Camb). 2001;18:1740–1741.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Sun C, Ou X, et al. Dual-targeted peptide-conjugated multifunctional fluorescent probe with AIEgen for efficient nucleus-specific imaging and long-term tracing of cancer cells. Chem Sci. 2017;8(6):4571–4578.
   PubMed Web of Science ®Google Scholar
• Li D, Ma Y, Du J, et al. Tumor acidity/NIR controlled interaction of transformable nanoparticle with biological systems for cancer therapy. Nano Lett. 2017;17(5):2871–2878.
   PubMed Web of Science ®Google Scholar
• Pang HH, Huang C-Y, Chou Y-W, et al. Bioengineering fluorescent virus-like particle/RNAi nanocomplexes act synergistically with temozolomide to eradicate brain tumors. Nanoscale. 2019;11(17):8102–8109.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xie X, Xu X, et al. Thermal and magnetic dual-responsive liposomes with a cell-penetrating peptide-siRNA conjugate for enhanced and targeted cancer therapy. Colloids Surf B Biointerfaces. 2016;146:607–615.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xie X, Yang Y, et al. Polymer nanoparticles modified with photo- and pH-dual-responsive polypeptides for enhanced and targeted cancer therapy. Mol Pharm. 2016;13(5):1508–1519.
   PubMedGoogle Scholar
• Li L, Sun W, Zhong J, et al. Multistage nanovehicle delivery system based on stepwise size reduction and charge reversal for programmed nuclear targeting of systemically administered anticancer drugs. Adv Funct Mater. 2015;25(26):4101–4113.
   Web of Science ®Google Scholar
• Zhong J, Li L, Zhu X, et al. A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery. Biomaterials. 2015;65:43–55.
   PubMed Web of Science ®Google Scholar
• He D, Müller K, Krhac Levacic A, et al. Combinatorial optimization of sequence-defined Oligo(ethanamino)amides for folate receptor-targeted pDNA and siRNA delivery. Bioconjug Chem. 2016;27(3):647–659.
   PubMed Web of Science ®Google Scholar
• Douat C, Bornerie M, Antunes S, et al. Hybrid cell-penetrating foldamer with superior intracellular delivery properties and serum stability. Bioconjug Chem. 2019;30(4):1133–1139.
   PubMed Web of Science ®Google Scholar
• Hibbitts A, O’Connor AM, McCarthy J, et al. Poly(ethylene glycol)-based peptidomimetic “PEGtide” of Oligo-Arginine allows for efficient siRNA transfection and gene inhibition. ACS Omega. 2019;4(6):10078–10088.
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D. Antinuclear antibodies: to penetrate or not to penetrate, that was the question. Lupus. 2001;10(5):315–318.
   PubMed Web of Science ®Google Scholar
• Weisbart RH, Stempniak M, Harris S, et al. An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications. J Autoimmun. 1998;11(5):539–546.
   PubMed Web of Science ®Google Scholar
• Turchick A, Liu Y, Zhao W, et al. Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells. Oncotarget. 2019;10(13):1272–1283.
   PubMedGoogle Scholar
• Schumacher D, Helma J, Schneider AFL, et al. Nanobodies: chemical functionalization strategies and intracellular applications. Angew Chem Int Ed Engl. 2018;57(9):2314–2333.
   PubMed Web of Science ®Google Scholar
• Herce HD, Schumacher D, Schneider AFL, et al. Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells. Nat Chem. 2017;9(8):762–771.
   PubMed Web of Science ®Google Scholar
• Tabtimmai L, Suphakun P, Srisook P, et al. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival. J Cell Biochem. 2019.
   Web of Science ®Google Scholar
• Akishiba M, Takeuchi T, Kawaguchi Y, et al. Cytosolic antibody delivery by lipid-sensitive endosomolytic peptide. Nat Chem. 2017;9(8):751–761.
   PubMed Web of Science ®Google Scholar
• Safa N, Vaithiyanathan M, Sombolestani S, et al. Population-based analysis of cell-penetrating peptide uptake using a microfluidic droplet trapping array. Anal Bioanal Chem. 2019;411(12):2729–2741.
   PubMed Web of Science ®Google Scholar
• Patel SG, Sayers EJ, He L, et al. Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines. Sci Rep. 2019;9(1):6298.
   PubMedGoogle Scholar
• Feiner-Gracia N, Olea RA, Fitzner R, et al. Super-resolution imaging of structure, molecular composition, and stability of single oligonucleotide polyplexes. Nano Lett. 2019;19(5):2784–2792.
   PubMed Web of Science ®Google Scholar
• Collado Camps E, Brock R. An opportunistic route to success: towards a change of paradigm to fully exploit the potential of cell-penetrating peptides. Bioorg Med Chem. 2018;26(10):2780–2787.
   PubMed Web of Science ®Google Scholar
• Freimann K, Arukuusk P, Kurrikoff K, et al. Optimization of in vivo DNA delivery with NickFect peptide vectors. J Control Release. 2016;241:135–143.
   PubMed Web of Science ®Google Scholar
• Kurrikoff K, Veiman K-L, Künnapuu K, et al. Effective in vivo gene delivery with reduced toxicity, achieved by charge and fatty acid -modified cell penetrating peptide. Sci Rep. 2017;7(1):17056.
   PubMedGoogle Scholar
• van Den Brand D, Gorris MAJ, van Asbeck AH, et al. Peptide-mediated delivery of therapeutic mRNA in ovarian cancer. Eur J Pharm Biopharm. 2019;141:180–190.
   PubMed Web of Science ®Google Scholar
• van Oppen L, Pille J, Stuut C, et al. Octa-arginine boosts the penetration of elastin-like polypeptide nanoparticles in 3D cancer models. Eur J Pharm Biopharm. 2019;137:175–184.
   PubMed Web of Science ®Google Scholar
• Patel NR, Aryasomayajula B, Abouzeid AH, et al. Cancer cell spheroids for screening of chemotherapeutics and drug-delivery systems. Ther Deliv. 2015;6(4):509–520.
   PubMed Web of Science ®Google Scholar